Full-Spectrum Hemp and Inflammation

Anti-inflammatory activity remains one of the most widely discussed and well-researched benefits of hemp-derived compounds. In this article, we break down how these naturally occurring cannabinoids help influence inflammatory pathways, both individually and as part of full-spectrum formulations.

What Is Inflammation?

According to the Mayo Clinic, inflammation is a natural part of the body’s immune response that becomes activated when the body detects injury, irritation, or potential threats. It is the body’s built-in protective system, designed to defend against harm and begin the healing process.

When inflammation is triggered, the body releases signaling molecules such as cytokines that coordinate how immune cells respond. In a balanced state, this response rises when needed and settles once the body has restored order. However, modern stressors, poor sleep, environmental exposure, and continuous irritation can sometimes keep this response active longer than intended, creating an internal environment that is harder for the body to regulate.

Inflammation can be classified into two main types:

• Acute inflammation is short-term and usually resolves within hours or days. It often includes redness, warmth, and swelling as the body sends immune cells to repair damaged tissue.
• Chronic inflammation is low-grade and can persist over weeks, months, or even years. Unlike acute inflammation, it may not be noticeable but can place ongoing stress on tissues.

Modern lifestyle factors can sometimes keep the body’s inflammatory response active longer than intended. Stress, poor-quality sleep, environmental pollutants, sedentary behavior, and dietary imbalances can all contribute to this prolonged state, creating a scenario where the body’s internal regulation becomes more difficult.

Cannabinoids with anti-inflammatory potentials

Cannabinoids are biologically active compounds that include naturally occurring molecules found in Cannabis sativa (like hemp), as well as structurally related compounds produced in the body (endocannabinoids) and synthetic analogues.  These molecules interact with the body’s endocannabinoid system (ECS), a network of receptors and signaling pathways that helps regulate many physiological processes, including the body’s inflammatory response. By influencing how the ECS communicates with immune cells, cannabinoids may play a role in supporting the body’s ability to maintain balance within its inflammatory pathways.

Hemp is a chemically complex plant containing more than 545 identified compounds spanning multiple chemical families including cannabinoids, terpenes, flavonoids, phenolic compounds, esters, ethers and more. So far, scientists have identified over 150 cannabinoids including well-known molecules such as CBD, CBDa, CBG, THCa, THC, THCV and CBC, over 150 different terpenes, which give hemp its characteristic aroma and contribute to its biological activity. In addition, hemp contains dozens of flavonoids, such as cannflavins, which are polyphenolic compounds studied for their potential health-related properties. Each of these compounds interacts with the ECS and other cellular targets in slightly different ways. 

CBD and Inflammation: What Research Suggests About Its Mechanisms

Cannabidiol (CBD) is one of the most studied cannabinoids in hemp, particularly for its potential role in supporting balanced inflammatory responses. While CBD does not directly bind strongly to the main cannabinoid receptors CB1 and CB2, it can influence them indirectly, helping the body regulate immune signaling and inflammatory pathways.

Research suggests CBD provides its anti-inflammatory effect via the following ways;

• Inhibition of Pro-Inflammatory Cytokines

One of the key ways CBD may influence inflammation is by reducing the production of pro-inflammatory signaling molecules, known as cytokines. These include IL-1β, IL-6, and TNF-α, which are released by immune cells to initiate and sustain inflammatory responses. By modulating the release of these cytokines, CBD may help “turn down” excessive inflammatory signaling, supporting the body’s ability to maintain balance.

• Antioxidant Properties

Inflammation is closely linked to oxidative stress, a condition where reactive molecules called free radicals (reactive oxygen species, or ROS) accumulate and overwhelm the body’s natural defenses. CBD has demonstrated antioxidant activity, helping to protect cells from oxidative damage. By supporting the body’s redox balance, CBD may indirectly reduce both the causes and consequences of inflammation.

• Modulation of the Endocannabinoid System (ECS)

The ECS regulates many physiological processes, including immune response and inflammation. Although CBD has a low direct binding affinity for the main cannabinoid receptors (CB1 and CB2), it can influence the system in several important ways. CBD can inhibit the breakdown of the body’s natural endocannabinoids, such as anandamide, allowing them to remain active longer and prolong their regulatory effects.

• Activation of the 15-Lipoxygenase (15-LOX) Enzyme

Emerging research indicates that CBD may activate 15-lipoxygenase (15-LOX), an enzyme responsible for producing specialized pro-resolving mediators (SPMs). SPMs actively help terminate inflammation, promote tissue repair, and restore homeostasis. This suggests that CBD not only modulates inflammatory signals but may also support the resolution of inflammation.

•       Interaction with Other Receptors and Channels

CBD also interacts with a variety of non-ECS targets that influence inflammation and pain perception including: TRPV1 (Transient Receptor Potential Vanilloid 1) which is involved in sensing pain and inflammatory signals; and 5-HT1A Serotonin Receptors responsible for regulating mood and pain perception.

CBDa and Inflammation

Cannabidiolic acid (CBDa) is the naturally occurring, “raw” form of CBD found in unprocessed hemp. Unlike CBD, which is produced when hemp is heated or decarboxylated, CBDa is present in its acidic form in fresh plant material. CBDa have been reported from research to provide anti-inflammatory properties through the following mechanisms.

• Direct Inhibition of COX-2

One of CBDa’s most well-studied mechanisms is its ability to inhibit the cyclooxygenase-2 (COX-2) enzyme. COX-2 is responsible for producing pro-inflammatory prostaglandins, the same molecules targeted by conventional NSAIDs like ibuprofen and celecoxib. By blocking COX-2, CBDa can reduce the production of these inflammatory mediators, helping to support balanced inflammatory responses. Some studies suggest that CBDa may be significantly more potent than CBD in this particular action.

• Interaction with Serotonin Receptors (5-HT1A)

CBDa also shows a strong affinity for the 5-HT1A serotonin receptor, which plays a role in regulating mood, anxiety, nausea, and pain perception. Research indicates that CBDa may bind to this receptor up to 1,000 times more strongly than CBD in certain models. Activation of 5-HT1A receptors can influence the release of anti-inflammatory mediators and reduce the transmission of pain signals, complementing its anti-inflammatory and analgesic potential.

• Modulation of Cytokine Production

Preliminary studies suggest that CBDa can also modulate immune signaling, helping to down-regulate pro-inflammatory cytokines such as  IFN-γ, which are key drivers of the inflammatory cascade. This mechanism is similar to CBD, but CBDa’s combination of COX-2 inhibition, serotonin receptor activity, and cytokine modulation provides a unique multi-target approach.

CBG and Inflammation

Cannabigerol (CBG) is a minor cannabinoid naturally present in most hemp strains, though certain strains, known as Type IV chemotypes, are bred to contain higher percentages of CBG. Unlike the more abundant cannabinoids such as CBD and THC, CBG has unique chemical properties that have attracted scientific interest for its broad anti-inflammatory potential through multiple molecular pathways. Some of these pathways are discussed below;

• Direct Modulation of Cannabinoid Receptors (CB1 and CB2)

Unlike CBD, which has low binding affinity, CBG interacts more directly with the core receptors of the endocannabinoid system (ECS). CBG acts as a weak agonist at CB1 receptors. While these receptors mediate the psychoactive effects of THC, CBG’s mild activation is non-intoxicating but may contribute to neuroprotective and anti-inflammatory effects in the brain and nervous system. CBG also partially activates CB2 receptors, which are highly expressed on immune cells. CB2 activation helps suppress pro-inflammatory signaling, reducing immune-mediated inflammation and pain.

• Interaction with TRP Channels (Ion Channels)

CBG modulates several Transient Receptor Potential (TRP) channels, which are crucial in regulating inflammation and pain. CBG is a potent agonist of the TRPA1 channel, which plays a central role in sensing inflammation and irritation. Modulation of TRPA1 may help desensitize chronic inflammatory pathways, particularly in autoimmune conditions like rheumatoid arthritis. CBG also interacts with TRPV1 and TRPV2 channels, contributing to broad analgesic and anti-inflammatory effects, similar to mechanisms observed with CBD.

• Suppression of Key Inflammatory Signaling Pathways

CBG down-regulates pro-inflammatory cytokines, including IL-6 and TNF-α, helping to prevent an overactive immune response. CBG inhibits the NF-κB signaling pathway, a master regulator of inflammatory gene expression to reduce the production of proteins that perpetuate inflammation.

• Other Unique Targets

CBG also engages additional molecular targets that contribute to anti-inflammatory and supportive effects: including α2-Adrenoreceptor, and PPAR-γ. Potent activation of α2-adrenoreceptors may aid in muscle relaxation, sedation, and pain modulation, indirectly supporting recovery from inflammation. CBG activates Peroxisome Proliferator-Activated Receptor γ (PPAR-γ), a nuclear receptor involved in anti-inflammatory and metabolic regulation, enhancing its overall regulatory profile.

CBC and Inflammation

Cannabichromene (CBC) is one of the “big six” cannabinoids and is a minor, non-intoxicating compound found in hemp. Certain hemp strains are bred to contain higher CBC levels, enhancing its potential biological effects. Although CBC is less abundant than CBD or THC, research shows it may contribute significantly to balanced inflammatory responses through a unique set of mechanisms that overlap with, yet are distinct from, CBD and CBG.

• Modulation of TRP Channels (Ion Channels)

CBC strongly interacts with Transient Receptor Potential (TRP) channels, which play central roles in both pain and inflammation signaling. These channels are key targets for cannabinoids in regulating how the body perceives and responds to inflammatory stimuli. CBC is considered the most potent activator of TRP channels among minor cannabinoids. One important interaction is with the TRPA1 channel, sometimes called the “wasabi receptor” because it is activated by irritants. CBC acts as a potent agonist of TRPA1. While activation initially sensitizes the pathway, it can subsequently desensitize it, helping to reduce chronic pain and inflammatory signaling over time. CBC also interacts with TRPV1 receptors, similar to how capsaicin from chili peppers works. This interaction contributes to both anti-inflammatory and analgesic effects, supporting pain relief while helping to modulate inflammatory responses.

• Inhibition of Pro-Inflammatory Signaling Pathways

CBC directly influences the cellular machinery that drives inflammation by targeting multiple key pathways. Research indicates that CBC can reduce the production of pro-inflammatory mediators, including nitric oxide (NO), inducible nitric oxide synthase (iNOS), and cytokines such as IL-1β, IL-6, and TNF-α. In addition, CBC suppresses the NF-κB and MAPK signaling pathways, which are central regulators of inflammatory gene expression. 

• CB2 Receptor Agonism

Unlike CBD, CBC is a CB2 receptor agonist, targeting receptors primarily on immune and peripheral nervous system cells. Activation of CB2 is a well-established mechanism for reducing inflammation without causing psychoactive effects, reinforcing CBC’s role in full-spectrum hemp extracts.

CBGa and inflammation

Cannabigerolic acid (CBGA) is the acidic precursor to major cannabinoids such as CBD, THC, and CBG, earning it recognition as the foundational cannabinoid in the hemp plant. Unlike its decarboxylated form CBG, CBGA exists primarily in raw, unheated hemp, and certain Type IV hemp chemotypes are bred to express naturally higher levels of acidic cannabinoids, including CBGA. Although research on CBGA is still emerging, early findings indicate that it plays an important and independent role in regulating inflammatory responses through several distinct molecular mechanisms.

• Inhibition of Pro-Inflammatory Cytokines

One of the most noted anti-inflammatory actions of CBGA is its ability to reduce the production of key inflammatory signaling molecules. Preclinical research, including in vitro inflammation models, shows that CBGA can suppress pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α. These cytokines act as major messengers that amplify and sustain the inflammatory response. 

• Modulation of Inflammatory Signaling Pathways

CBGA also influences critical cellular pathways involved in inflammation. Studies in human keratinocytes suggest that CBGA can modulate the MAPK (Mitogen-Activated Protein Kinase) pathway, a central regulator of how cells respond to stress and inflammatory triggers. Disrupting MAPK activity is a well-recognized strategy for downregulating inflammatory gene expression. In addition, CBGA functions as a dual agonist of PPAR-α and PPAR-γ receptors, nuclear receptors involved in metabolic regulation and inflammation control. Activation of these receptors has been associated with reduced inflammatory activity and improved cellular balance, highlighting CBGA’s diverse biological reach.

• Interaction with Ion Channels

CBGA interacts with key ion channels that help regulate pain, inflammation, and cellular stress responses. Notably, CBGA is the most potent cannabinoid studied to date for inhibiting the TRPM7 ion channel, which is associated with inflammatory conditions and kidney injury. In vivo studies have shown that TRPM7 inhibition by CBGA can protect against tissue damage while reducing inflammatory cytokine expression.

CBGA may also interact with the TRPV1 receptor, an important channel involved in pain, heat sensitivity, and inflammatory signaling. 

Varin cannabinoids and inflammation

Varin cannabinoids such as THCV, CBDV, CBCV, and CBDVa demonstrate distinct anti-inflammatory potential shaped by their shorter three-carbon side chain, which changes how they influence the body’s immune and inflammatory networks. These cannabinoids help reduce key pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 while modulating enzymes such as COX and iNOS that fuel inflammatory mediator production. THCV provides dual activity at CB1 and CB2 receptors, supporting both immune balance and tissue-calming effects. CBDV and CBDVa show strong regulatory activity on neuroinflammatory processes, partly through TRP channel modulation and MAPK pathway balancing, helping to reduce inflammatory signaling at the cellular level.

References:

1. Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants, 9(1), 21. https://doi.org/10.3390/antiox901002 
2. Booth, J. K., & Bohlmann, J. (2019). Terpenes in Cannabis sativa – From plant genome to humans. Plant Science, 284, 67–72. https://doi.org/10.1016/j.plantsci.2019.03.022 
3. Coolong, T. (2025, August 13). An Introduction to Hemp Chemistry and Lab Results | CAES Field Report. CAES Field Report. https://fieldreport.caes.uga.edu/publications/C1209/an-introduction-to-hemp-chemistry-and-lab-results/ 
4. Cosentino, M., Legnaro, M., Luini, A., Ferrari, M., Sodergren, M., Pacchetti, B., & Marino, F. (2022). Effect of Cannabidiol on Cyclooxygenase Type 1 and 2 Expression and Function in Human Neutrophils. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2022.0008 
5. Esmaeel Ghasemi Gojani, Wang, B., Li, D.-P., Kovalchuk, O., & Kovalchuk, I. (2023). Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. Molecules, 28(18), 6487–6487. https://doi.org/10.3390/molecules28186487 
6. Gugliandolo, A., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2018). In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid. International Journal of Molecular Sciences, 19(7), 1992. https://doi.org/10.3390/ijms19071992 
7. Hahm, S., Lee, Y., Lee, K., & Park, J. (2024). Optimization of Cannabinoid Production in Hemp Through Methyl Jasmonate Application in a Vertical Farming System. Horticulturae, 10(11), 1165–1165. https://doi.org/10.3390/horticulturae10111165 
8. Henshaw, F. R., Dewsbury, L. S., Lim, C. K., & Steiner, G. Z. (2021). The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. Cannabis and Cannabinoid Research, 6(3), 177–195. https://doi.org/10.1089/can.2020.0105 
9. Jeong, G. H., Kim, K. C., & Lee, J. H. (2025). Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. Cells, 14(2), 83. https://doi.org/10.3390/cells14020083 
10. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94–e94. https://doi.org/10.1038/tp.2012.15 
11. Li, S., Li, W., Malhi, N. K., Huang, J., Li, Q., Zhou, Z., Wang, R., Peng, J., Yin, T., & Wang, H. (2024). Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. Molecules (Basel, Switzerland), 29(22), 5471. https://doi.org/10.3390/molecules29225471 
12. Mendoza, S. (2025). The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. AIMS Neuroscience, 12(1), 32–43. https://doi.org/10.3934/neuroscience.2025003 
13. Nigro, E., Pecoraro, M. T., Formato, M., Piccolella, S., Ragucci, S., Mallardo, M., Russo, R., Di Maro, A., Daniele, A., & Pacifico, S. (2022). Cannabidiolic acid in Hemp Seed Oil Table Spoon and Beyond. Molecules, 27(8), 2566. https://doi.org/10.3390/molecules27082566 
14. noble.dana. (2024, January 3). Chronic inflammation: What it is, why it’s bad, and how you can reduce it. Mayo Clinic Press. https://mcpress.mayoclinic.org/dairy-health/chronic-inflammation-what-it-is-why-its-bad-and-how-you-can-reduce-it/ 
15. Peltner, L. K., Lars Gluthmann, Friedemann Börner, Pace, S., Hoffstetter, R. K., Kretzer, C., Bilancia, R., Pollastro, F., Koeberle, A., Appendino, G., Rossi, A., Newcomer, M. E., Gilbert, N. C., Werz, O., & Jordan, P. M. (2023). Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2023.08.001 
16. Sepulveda, D. E., Vrana, K. E., Kellogg, J. J., Bisanz, J. E., Desai, D., Graziane, N. M., & Raup-Konsavage, W. M. (2024). The Potential of Cannabichromene (CBC) as a Therapeutic Agent. Journal of Pharmacology and Experimental Therapeutics, JPET-MR-2024-002166. https://doi.org/10.1124/jpet.124.002166 
17. Suzuki, S., Wakano, C., Monteilh-Zoller, M. K., Cullen, A. J., Fleig, A., & Penner, R. (2023). Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. Function, 5(1). https://doi.org/10.1093/function/zqad069 
18. Tortolani, D., Di Meo, C., Standoli, S., Ciaramellano, F., Kadhim, S., Hsu, E., Rapino, C., & Maccarrone, M. (2023). Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. International Journal of Molecular Sciences, 24(3), 2721. https://doi.org/10.3390/ijms24032721 
19. Udoh, M., Santiago, M., Devenish, S., McGregor, I. S., & Connor, M. (2019). Cannabichromene is a cannabinoid CB 2 receptor agonist. British Journal of Pharmacology, 176(23), 4537–4547. https://doi.org/10.1111/bph.14815 
20. Walsh, K. B., McKinney, A. E., & Holmes, A. E. (2021). Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.777804
21. Wang, X., Lin, C., Wu, S., Zhang, T., Wang, Y., Jiang, Y., & Wang, X. (2022). Cannabidivarin alleviates neuroinflammation by targeting TLR4 co-receptor MD2 and improves morphine-mediated analgesia. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.929222